The donor-derived cell-free DNA (dd-cfDNA) monitoring segment leads the Kidney Transplant AlloSure dd-cfDNA Monitoring Market by test type with a 35.7% share in 2026. Acute rejection monitoring accounts for 30.6% by application, transplant centers hold 37.1% by end user, and deceased donor kidney transplantation represents 33.0% by transplant type.